A Phase 2 dose-ranging study of IONIS APOCIII LRx in patients with hypertriglyceridemia and established cardiovascular disease .

Trial Profile

A Phase 2 dose-ranging study of IONIS APOCIII LRx in patients with hypertriglyceridemia and established cardiovascular disease .

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs IONIS APOCIII LRx (Primary)
  • Indications Cardiovascular disorders; Hypertriglyceridaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Aug 2017 Accordign to an Akcea Therapeutics media release, the company plans to initiate this study in the second half of 2017.
    • 09 May 2017 Accordign to an Ionis Pharmaceuticals media release, the company plans to initiate this study later in 2017
    • 12 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top